Cervical Cancer

P=N/A, N=280, Not yet recruiting, Qilu Hospital of Shandong University

Moreover, the half-maximum inhibitory concentration (IC50) values for 85 drugs, such as roscovitine and embelin, were markedly distinct between the two risk groups...RT-qPCR results confirmed that TNF, PTPN6, FASN, and TFRC were upregulated in CESC, consistent with the Wilcoxon test findings. This study established an MCD-associated prognostic model for CESC, highlighting its link to the TME and its potential to enhance prognostic predictions.

Our findings reveal that WT1-AS functions as a tumor suppressor in CESC by promoting apoptosis and identify OSR2 as a novel upstream regulator. The WT1-AS/OSR2 axis may have biological and potential prognostic relevance in CESC, although its clinical applicability requires further validation.

It also considerably reduced NF-kB p65 and inflammatory markers in comparison with cisplatin alone. Our study demonstrated that rhIGFBP-3 enhanced cisplatin efficacy by promoting apoptosis and attenuating inflammation, highlighting its potential as both a cisplatin adjuvant and a monotherapy in HeLa cells.

Cancer-associated fibroblast FAP immunoreactivity in this series indicates that [212Pb]Pb-PSV-359 radiopharmaceutical therapy might have usefulness in women with persistent, recurrent or metastatic uterine cervix cancer. A phase I clinical trial inclusive of metastatic uterine cervix cancer patients is underway (NCT06710756).

Optimization of cycle threshold cut-offs yielded 93% sensitivity and 77% specificity for predicting CIN2+ in an enriched population. It can enhance accessibility, compliance, and early detection across diverse clinical settings.

Extended HR-HPV genotyping using the BD Onclarity assay demonstrated a high prevalence of HR-HPV in this high-risk population, with multiple genotype infections commonly observed. While non-HPV16/18 genotypes predominated overall, HPV16 was more frequently associated with abnormal cytologic and high-grade histologic findings. Given the limited number of biopsy-confirmed high-grade lesions, these associations should be interpreted as descriptive and hypothesis-generating. Cytology remains central to anal cancer screening, with extended HPV genotyping serving as a complementary adjunct rather than a standalone stratification tool. Larger longitudinal studies with systematic histopathologic follow-up are needed to clarify the clinical significance of extended HPV genotyping in this population.

Three ADCs are currently approved for previously treated gynaecological cancers: mirvetuximab soravtansine for folate receptor-α-positive ovarian cancer, trastuzumab deruxtecan for solid tumours expressing HER2 (defined as a staining intensity on immunohistochemistry of 3+) and tisotumab vedotin for cervical cancer (independent of tissue factor expression). Moreover, rational combinations could reinforce and extend the clinical potential of these agents, as has already been demonstrated with the addition of ADCs to immune checkpoint inhibitors in an effort to amplify antitumour immunity and prolong the durability of clinical responses. In this Review, we provide an overview of the current landscape of ADCs in gynaecological malignancies, highlighting key advances and future opportunities.

Our findings suggest HIV-1 dysregulates cervical cell signaling via paracrine mechanisms to phenocopy PIK3CA-activating mutations through IRS1-PI3K-AKT pathway activation. Our findings highlight IRS1 and the PI3K pathway as a potential therapeutic target for cervical cancer in women living with HIV-1.

Early recognition and management are crucial for improving patient prognosis. A thorough understanding of the pathogenesis of ICI-IA is essential for optimizing treatment strategies and improving quality of life.

P1, N=12, Recruiting, University Medical Center Groningen

P2, N=134, Active, not recruiting, Grupo Español de Investigación en Cáncer de Ovario | Trial primary completion date: Dec 2025 --> Jul 2028 | Trial completion date: Dec 2025 --> Jul 2028